Renal and vascular effects of C-type and atrial natriuretic peptides in humans

ISABELLE PHAM,1 SAÏD SEDIAME,1 GENEVIÈVE MAISTRE,2 FRANÇOISE ROUDOT-THORAVAL,1 PIERRE-ETIENNE CHABRIER,3 ALAIN CARAYON,2 AND SERGE ADNOT1

1Service de Physiologie et d’Explorations Fonctionnelles, Hôpital Henri Mondor, 94000 Créteil; 2Service de Biochimie, Hôpital de la Pitié-Salpêtrière, 75013 Paris; and 3Institut Beaufour, 91952 Les Ulis, France

Pham, Isabelle, Said Sediame, Geneviève Maistre, Françoise Roudot-Thoraval, Pierre-Etienne Chabrier, Alain Carayon, and Serge Adnot. Renal and vascular effects of C-type and atrial natriuretic peptides in humans. Am. J. Physiol. 273 (Regulatory Integrative Comp. Physiol. 42): R1457–R1464, 1997.—C-type natriuretic peptide (CNP) may affect renal and vascular functions differently from atrial natriuretic peptide (ANP). The objective of this study was to compare the renal and vascular actions of CNP to those of ANP in normal men. CNP or ANP (0.005, 0.01, and 0.05 µg·kg⁻¹·min⁻¹) were given by infusion to eight healthy volunteers. CNP caused dose-dependent increases in natriuresis (UNa) and in the fractional excretion of sodium (FENa) with no effect on diuresis (UV), renal plasma flow, and glomerular filtration rate (GFR). Fraction of filtration (FF) increased only with the 0.05 µg·kg⁻¹·min⁻¹ CNP dose. ANP caused larger increases in UNa, FENa, and FF than CNP and also increased UV at 0.01 and 0.05 µg·kg⁻¹·min⁻¹ and GFR at 0.05 µg·kg⁻¹·min⁻¹. Although the ANP and CNP infusions produced similar elevation in the respective peptides plasma levels, urinary and nongenous guanosine 3′,5′-cyclic monophosphate increased less in response to CNP than to ANP. Blood pressure, forearm blood flow, plasma renin activity, and aldosterone remained unaffected during the peptides infusion. Plasma ANP increased slightly during CNP infusion. Our data indicate a higher threshold of renal response to CNP than to ANP. In contrast to ANP, CNP probably may not act as an endocrine factor in humans.

c-type natriuretic peptide (CNP) belongs to the natriuretic peptide family, which also includes the atrial natriuretic (ANP) and the brain natriuretic peptide (BNP). Three different receptors for natriuretic peptides have been identified. ANPR-A and ANP-B receptors (ANPR-A and -B) are coupled with the particulate guanylate cyclase, whereas the ANP-C receptor (ANPR-C) is not. Although ANPR-C plays a central role in ANP clearance, it may be linked to a second messenger signaling system and have other actions (19, 20). ANPR-A preferentially binds to ANP or BNP, whereas the selective ligand of ANPR-B appears to be CNP. CNP is produced by the central nervous system (29) and in smaller amounts by the kidneys (12, 22, 24, 32) and the vascular endothelial cells (28, 31). Production of both CNP and its receptor ANPR-B has been also demonstrated in the kidney (6), leading several investigators to speculate that CNP may act as an autocrine or paracrine factor in this organ (6, 12, 22, 24, 32).

Recent in vitro and in vivo studies have demonstrated biological effects of CNP that differ from those of ANP or BNP. CNP has been found to be a potent vasodilator but a weak natriuretic factor in various species of laboratory animals (9, 27). When infused in anesthetized dogs, CNP was more potent than ANP in causing hypotension but did not exhibit any natriuretic effect (9). In contrast, studies of isolated arterial rings from normal and spontaneously hypertensive rats found less relaxation with CNP than with ANP (33, 34). In normal volunteers receiving CNP as a continuous infusion, natriuresis either increased slightly or remained unchanged, and blood pressure did not vary (7, 16). Moreover, direct infusion of CNP into the brachial artery of normal subjects or patients with heart failure caused a smaller increase in forearm blood flow (FBF) than ANP (23).

Hence, the vascular and renal effects of CNP remain to be assessed in normal man, especially in reference to those of ANP (1). In the present study, we examined the effects of incremental rates of CNP infusion on renal excretory function, renal hemodynamics, FBF, and blood volume regulatory hormones in comparison with ANP at similar infusion rates in eight normal healthy subjects.

SUBJECTS AND METHODS

Subjects. Eight male students with a mean age ± SD of 23.5 ± 1.5 yr (range: 21–26 yr), a mean weight of 70.6 ± 5.5 kg (range: 60–76 kg), and a mean body surface area of 1.86 ± 0.1 m² (range: 1.67–1.96 m²) gave their informed consent to the study, which was approved by the Ethics and Research Committee of the Henri Mondor Hospital. None of the subjects had clinical evidence of cardiac and renal diseases and none were on medication. Each subject took 2 g of salt orally per day as a supplement to a normal sodium diet 8 days before each test and on the test day.

Study protocols. The subjects were studied on three occasions, at intervals of 8 days. ANP, CNP, and saline were each tested on one of the 3 days, in random order. All studies were conducted in the morning, 2 h after a light breakfast. The subjects were weighed and then remained supine except during the urine collections. Catheters were inserted into a superficial vein of both forearms for infusions and blood sampling, respectively. A 15 ml/kg oral water load was given in 15 min, before the infusion was begun, and the subjects were asked to void their bladder. An equilibration period of 120 min was followed by a baseline phase composed of 30-min urine collection periods; an infusion phase during which the subjects received either saline, ANP, or CNP; and a 30-min recovery phase. For the ANP and CNP infusions, sterile and aphyrogenic preparations of crystallized synthetic human α-ANP fragment 1–28 or CNP-22 (Novabiochem, Laufelfingen, Switzerland) were diluted in 50 ml normal saline to a 10 ng/ml concentration. ANP and CNP were

0363-6119/97 $5.00 Copyright © 1997 the American Physiological Society R1457
infused at incremental doses of 0.005 µg·kg\(^{-1}\)·min\(^{-1}\) during twophasest of 30 min, 0.01 µg·kg\(^{-1}\)·min\(^{-1}\) during 30 min, and
0.05 µg·kg\(^{-1}\)·min\(^{-1}\) during 30 min.

Renal measurements. Glomerular filtration rate (GFR) and
renal plasma flow (RPF), both corrected for body surface area,
were assessed by inulin (C\(\text{In}\)) and p-aminophenylphosphate (PAH)
steady-state clearances (C\(\text{PAH}\)), respectively. Inulin (Inutest
polyfurocane; Boehringer-Mannheim, Mannheim, Germany)
and PAH (Laboratoires SERB, Paris, France) were given as a
priming bolus of 40 and 10 mg/kg, respectively, and followed by
an intravenous infusion designed to produce a stable plasma
development after 120 min. At every 30-min interval through-
out the study, venous blood and urine samples for plasma and
urine output measurement were collected and the subjects were
asked to drink 150 ml of water. Inulin and PAH concentrations
were calculated using standard spectrophotometric methods.
Values were calculated according to the following standard
formulas: C\(\text{In}\) in ml·min\(^{-1}\)·1.73 m\(^2\) = UV·[ln][ln], where
UV is urine volume, brackets indicate concentration,
and U and P indicate urine and plasma, respectively; C\(\text{PAH}\) in
ml·min\(^{-1}\)·1.73 m\(^2\) = UV·[PAH]U/[PAH]P; filtration fraction
(in %) = C\(\text{PAH}\)/C\(\text{PAH}\); sodium excretion (U\(\text{Na}\)V; in mma/min) =
[\(\text{Na}\)U]/UV; sodium fractional excretion (in %) = (U\(\text{Na}\)V/\[\(\text{Na}\)P]\)/C\(\text{In}\); renal blood flow (RBF; in ml·min\(^{-1}\)·1.73 m\(^2\) = RF/(1
hematocrit); and renal vascular resistance (in IU) = mean
arterial pressure (MAP)·RBF.

Circulatory measurements. Heart rate and MAP were
measured every 15 min using a Finapress automatic device.
Determinations of FBF were performed by venous occlusion
plethysmography during the baseline phase, the peptide
measured every 15 min using a Finapress automatic device.
arterial pressure (MAP)/RBF.

Gly, and 0.1 mg aprotinin. All tubes were centrifuged at 3,500
milliliters of forearm volume. Forearm vascular resistances
were calculated by dividing the MAP by FBF.

Plasma hormone measurements. Blood samples were col-
collected in polypropylene chilled tubes containing 10 mg EDTA,
5 mg trypsin inhibitor, 17.4 mg phenylmethylsulfonyl fluo-
rside, and 0.1 mg aprotinin. All tubes were centrifuged at 3,500
g for 20 min and at 4°C. Plasma was stored at −80°C for
subsequent analysis.

ANP and CNP radioimmunoassays were performed after
extraction of 1–2 ml of plasma with Vycor glass (Corning
Glassware). The antisera used for ANP (RAS 8798, rabbit
anti-α-atrial natriuretic polypeptide serum; Peninsula Labo-
ratories) exhibited a high cross-reactivity with human α-ANP
(100%) and rat ANP (100%). The assay half-maximal inhibi-
tory concentration (IC\(_{50}\)) was ~25 pg. For CNP, the antibody
(RAS 9030, rabbit anti-CNP-22 serum; Peninsula Laborato-
ries) had 100% cross-reactivity with human, porcine, and rat
CNP-22 and porcine CNP-53 and exhibited no cross-reactiv-
ity with rat α-ANP and human α-ANP and BNP-32. Tyr-
CNP-22 was radiiodinated with \(^{125}\)I at 2,000 Ci/mmol using
the lactoperoxidase/hydrogen peroxide method. After incuba-
tion of the samples with the antisera and the \(^{125}\)I-CNP, the
bound and the free fractions were separated with charcoal
and the pellets were counted. The limit of detection was 2.5
pg/tube and the IC\(_{50}\) was 14.5 pg.

Plasma renin activity (PRA) was determined indirectly
via the generation of angiotensin I (angiotensin I radioimmunoas-
say kit SB-REN-2; ORIS, Gif-sur-Yvette, France) and ex-
pressed as nanograms per milliliter per hour.

Plasma aldosterone was determined by use of a radioimmu-
noassay kit (SB-ALDO-2, ORIS) and expressed as picograms
per milliliter.

Plasma and urinary guanosine 3′,5′-cyclic monophosphate
(cGMP) were measured with a commercial radioimmunoas-
say kit (cGMP \(^{125}\)) radioimmunoassay kit, DuPont NEX-133).
Net renal generation of cGMP, i.e., nephrogenous cGMP, was
calculated as the difference cGMP\(_{\text{f}}\)·F GR = U\(_{\text{cGMP}}\)·V (pmol/
min).

Statistical analysis. All data are expressed as means ± SD.
Analysis of variance (ANOVA) for repeated measurements
was used to study interactions between peptides and time. If
a significant interaction was found, factorial ANOVA was
performed to compare the effect of the two peptides at each
time point. To compare the effects of infusion rates on the
plasma peptide concentrations, an ANOVA model for re-
peated measurements and covariates (infusion rates) chang-
ing over trials (BMDP statistical software, 2 V program) was
performed. P values <0.05 were considered significant.

RESULTS

No adverse effects occurred during any of the study.
During the control study (administration of saline), diuresis
decreased (F = 4.2; P < 0.01; Fig. 1), whereas
urinary sodium concentration (F = 7.1, P < 0.001; Fig.
2), natriuresis (F = 7; P < 0.001; Fig. 2), and fractional
excretion of sodium (F = 8.7; P < 0.001; Fig. 3)
increased significantly with time. GFR, RPF, and filtra-
tion fraction remained unchanged (Table 1).

Infusion of ANP was associated with increases in
diuresis (Fig. 1), natriuresis (Fig. 2), and fractional
excretion of sodium (Fig. 3). Urinary sodium concentra-
tion did not increase with ANP compared with control
(Fig. 2). The increases in diuresis, natriuresis, and
fractional excretion of sodium were dose dependent
significant increases occurred for diuresis and natriuresis with the 0.01 and 0.05 µg·kg⁻¹·min⁻¹ infusion rates and for fractional excretion of sodium with the 0.005, 0.01, and 0.05 µg·kg⁻¹·min⁻¹ infusion rates. Kaliuresis remained unchanged during ANP infusion (not shown). GFR increased in response to the highest dose of ANP (0.05 µg·kg⁻¹·min⁻¹) (F = 8.8; P < 0.001) and CNP (F = 8.2; P < 0.001). *P < 0.05, **P < 0.01, ***P < 0.001 vs. saline infusion (control).

Infusion of CNP also caused increases in natriuresis (Fig. 2) and fractional excretion of sodium (Fig. 3), with no change in diuresis (Fig. 1) or kaliuresis (not shown). As natriuresis increased with no change in diuresis, urinary sodium concentration increased by 38 ± 5.1 mmol/ml in response to the highest CNP infusion rate, whereas only a 16 ± 2.6 mmol/ml increase was measured during saline infusion (P < 0.001). GFR, RPF, and renal vascular resistance remained unchanged during CNP infusion (Table 1). However, the filtration fraction increased in response to the highest CNP infusion rate (F = 2.8; P < 0.05) (Table 1). The effects of CNP on natriuresis (F = 3.1; P < 0.01), fractional excretion of sodium (F = 3.8; P < 0.01), and filtration fraction (F = 2.2; P < 0.05) were significantly smaller than those induced by ANP (Figs. 2 and 3 and Table 1).

Blood pressure, heart rate, FBF, and forearm vascular resistance were unaffected by ANP or CNP infusions (Table 2).

Plasma ANP (Fig. 4), PRA, and aldosterone (Table 3) remained unchanged during the control study (Fig. 5). Plasma CNP remained at the limit of detection (<0.5 pg/ml). Nor were there any changes in plasma and urinary cGMP concentrations or in nephrogenous cGMP (Fig. 6). During ANP infusion, plasma ANP increased 2- to 10-fold depending on the ANP infusion rate (Fig. 4), whereas plasma CNP remained at the limit of detection (Fig. 5). ANP infusion was associated with concomitant dose-dependent increases in levels of plasma, urinary, and nephrogenous cGMP (Fig. 6). Infusion of ANP also had no effect on PRA and plasma aldosterone, although there was a trend toward a decrease in PRA (Table 3). During CNP infusion, plasma CNP increased in a dose-dependent fashion (Fig. 5). To compare changes in plasma ANP and CNP levels during the peptide infusions, we compared the magnitudes of ANP and CNP level increases at increasing infusion rates, taking into account the difference in the molar infusion rate between ANP and CNP due to the different molecular weights of these two peptides. The plasma level increases produced by the peptide infusions were not significantly different between ANP and CNP, as shown in Fig. 7. However, due to the lower molecular weight of
CNP compared with ANP, at a given infusion rate the molar concentration of CNP was higher during CNP infusion than the molar concentration of ANP during ANP infusion. Infusion of CNP induced a 1.5-fold increase in urinary cGMP with no change in plasma nucleotide concentration. Nephrogenous cGMP increased significantly in response to the highest CNP infusion rate (Fig. 6). Infusion of CNP was also associated with a slight but significant increase in plasma ANP concentration (Fig. 4), with no change in PRA and plasma aldosterone concentration (Table 3). CNP had significantly smaller effects than ANP on plasma ANP concentration (F = 41; P < 0.001), urinary cGMP excretion (F = 10.6; P < 0.001), and renal generation of cGMP (F = 2.8; P < 0.05).

**DISCUSSION**

We found that infusion of CNP in normal subjects was associated with increases in natriuresis, fractional excretion of sodium, urinary cGMP, and nephrogenous cGMP with no changes in blood pressure and FBF. ANP infusion induced similar changes with, however, a greater effect on renal function. Although the increases in circulating ANP and CNP levels produced by the peptide infusions were of similar magnitude, the threshold of renal response for CNP was higher than for ANP. Differences in the renal effects of exogenous ANP infusion in humans according to the dose have been reported. Whereas high doses of ANP induced natriuresis and altered renal hemodynamics, lower doses selectively increased natriuresis but had no effect on renal hemodynamic parameters (2, 3, 13, 15, 25). In our study, infusion of ANP at the rate of 0.01 µg·kg⁻¹·min⁻¹, providing a three- to sixfold increase in plasma ANP concentration, resulted in increases in diuresis, natriuresis, and sodium fractional excretion with no change in GFR or RPF. Infusion of ANP at the highest rate of 0.05 µg·kg⁻¹·min⁻¹, providing a 10-fold increase in

### Table 1. Effects of ANP and CNP infusions on renal hemodynamics: GFR, RPF, FF, and RVR

<table>
<thead>
<tr>
<th></th>
<th>Baseline 1</th>
<th>Baseline 2</th>
<th>30 min 0.005</th>
<th>60 min 0.005</th>
<th>0.01</th>
<th>0.05</th>
<th>Recovery</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GFR, ml·min⁻¹·1.73 m⁻²</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>109.3 ± 12.5</td>
<td>111 ± 12.2</td>
<td>111.1 ± 17.5</td>
<td>103.1 ± 16.2</td>
<td>109 ± 13.9</td>
<td>112.4 ± 12.3</td>
<td>112.4 ± 12.3</td>
</tr>
<tr>
<td>ANP</td>
<td>102.5 ± 16.4</td>
<td>104.3 ± 15.5</td>
<td>110.3 ± 15.3</td>
<td>97 ± 12.6</td>
<td>103 ± 12.1</td>
<td>118.9 ± 21.7*</td>
<td>106 ± 14.8</td>
</tr>
<tr>
<td>CNP</td>
<td>107.3 ± 19.8</td>
<td>111.8 ± 16.3</td>
<td>115.6 ± 13.6</td>
<td>108.6 ± 16.7</td>
<td>114.9 ± 20.2</td>
<td>118 ± 23.9</td>
<td>112.5 ± 19.3</td>
</tr>
<tr>
<td><strong>RPF, ml·min⁻¹·1.73 m⁻²</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>521.3 ± 83.3</td>
<td>525.5 ± 78.7</td>
<td>505.3 ± 96.8</td>
<td>485.1 ± 88.2</td>
<td>487.1 ± 65.4</td>
<td>535.4 ± 74.3</td>
<td>535.4 ± 74.3</td>
</tr>
<tr>
<td>ANP</td>
<td>506.8 ± 93.6</td>
<td>483.6 ± 48.2</td>
<td>512.3 ± 60.4</td>
<td>431.4 ± 67.3</td>
<td>480 ± 61.6</td>
<td>476.1 ± 93</td>
<td>436.8 ± 63.9</td>
</tr>
<tr>
<td>CNP</td>
<td>493.7 ± 100.4</td>
<td>551.8 ± 107.1</td>
<td>520.6 ± 91.5</td>
<td>477.6 ± 118.4</td>
<td>519.8 ± 102.1</td>
<td>518.8 ± 95.2</td>
<td>485 ± 127.5</td>
</tr>
<tr>
<td><strong>FF, %</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>21.8 ± 2.3</td>
<td>21.8 ± 1.9</td>
<td>22.4 ± 2.1</td>
<td>21.5 ± 1.2</td>
<td>21.9 ± 1.9</td>
<td>21.4 ± 2.3</td>
<td>21.4 ± 2.3</td>
</tr>
<tr>
<td>ANP</td>
<td>20.6 ± 3.8</td>
<td>21.9 ± 2.4</td>
<td>21.9 ± 2.8</td>
<td>22.9 ± 2.9</td>
<td>22.9 ± 3.7</td>
<td>25.9 ± 4.8†</td>
<td>26.4 ± 6.4†</td>
</tr>
<tr>
<td>CNP</td>
<td>21.1 ± 5.5</td>
<td>20.6 ± 3.4</td>
<td>23 ± 5.7</td>
<td>23.6 ± 5.5</td>
<td>22.4 ± 3.1</td>
<td>23 ± 4.1*</td>
<td>23.8 ± 3.8*</td>
</tr>
<tr>
<td><strong>RVR, IU</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>163 ± 31</td>
<td></td>
<td>160 ± 39</td>
<td>167 ± 29</td>
<td>145 ± 26</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ANP</td>
<td>166 ± 33</td>
<td></td>
<td>173 ± 34</td>
<td>156 ± 33</td>
<td>172 ± 34</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CNP</td>
<td>154 ± 40</td>
<td></td>
<td>164 ± 31</td>
<td>156 ± 29</td>
<td>159 ± 31</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Data are means ± SD. Infusion rates of atrial (ANP) and C-type (CNP) natriuretic peptides are expressed in µg·kg⁻¹·min⁻¹. For renal vascular resistance (RVR), the baseline and 0.005 µg·kg⁻¹·min⁻¹ values are the means of 2 calculations. Effects of ANP were not significant on renal plasma flow (RPF) (F = 1.7; NS) or RVR (F = 1.9; NS), and those of CNP were not significant on glomerular filtration rate (GFR) (F = 0.7; NS), RPF (F = 0.8, NS), and RVR (F = 0.8; NS). FF, filtration fraction. *P < 0.05 and †P < 0.01 vs. saline infusion (control).

### Table 2. Effects of ANP and CNP infusions on MAP, HR, FBF, and FVR

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>0.005</th>
<th>0.01</th>
<th>0.05</th>
<th>Recovery</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MAP, mmHg</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>81.4 ± 5.2</td>
<td>80.1 ± 6.8</td>
<td>78.2 ± 7.6</td>
<td>80.6 ± 6.9</td>
<td>80.2 ± 6.3</td>
</tr>
<tr>
<td>ANP</td>
<td>81.6 ± 6.5</td>
<td>78.9 ± 6.3</td>
<td>77.6 ± 4.3</td>
<td>79.3 ± 5.2</td>
<td>79.4 ± 4.7</td>
</tr>
<tr>
<td>CNP</td>
<td>79.6 ± 6.1</td>
<td>79.1 ± 3.9</td>
<td>78.6 ± 4.5</td>
<td>79.9 ± 3.8</td>
<td>79.3 ± 3.7</td>
</tr>
<tr>
<td><strong>HR, beats/min</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>56.7 ± 9.7</td>
<td>57 ± 7.1</td>
<td>57 ± 7</td>
<td>57 ± 7</td>
<td>56.9 ± 7.1</td>
</tr>
<tr>
<td>ANP</td>
<td>54 ± 5.5</td>
<td>54.9 ± 8.1</td>
<td>58.8 ± 8.8</td>
<td>56.1 ± 7.8</td>
<td>55.8 ± 7.3</td>
</tr>
<tr>
<td>CNP</td>
<td>55.4 ± 7.8</td>
<td>55.9 ± 7.2</td>
<td>54.8 ± 5.5</td>
<td>55.9 ± 7.3</td>
<td>55.5 ± 6.8</td>
</tr>
<tr>
<td><strong>FBF, ml·min⁻¹·100 ml⁻¹</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>1.7 ± 0.6</td>
<td>1.8 ± 0.7</td>
<td>2 ± 1.1</td>
<td>1.8 ± 0.8</td>
<td>1.8 ± 0.8</td>
</tr>
<tr>
<td>ANP</td>
<td>1.4 ± 0.5</td>
<td>1.5 ± 0.4</td>
<td>1.7 ± 0.7</td>
<td>1.6 ± 0.5</td>
<td>1.4 ± 0.4</td>
</tr>
<tr>
<td>CNP</td>
<td>1.9 ± 0.8</td>
<td>1.8 ± 0.8</td>
<td>1.6 ± 0.8</td>
<td>1.6 ± 0.7</td>
<td>1.7 ± 0.7</td>
</tr>
<tr>
<td><strong>FVR, IU</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>55.1 ± 19.5</td>
<td>49.8 ± 19</td>
<td>47.5 ± 20</td>
<td>51.1 ± 20.5</td>
<td>50.8 ± 20</td>
</tr>
<tr>
<td>ANP</td>
<td>67.7 ± 41</td>
<td>54.7 ± 25.1</td>
<td>56.2 ± 32.1</td>
<td>56 ± 22.2</td>
<td>62.5 ± 20.5</td>
</tr>
<tr>
<td>CNP</td>
<td>49.9 ± 20.3</td>
<td>52.1 ± 19</td>
<td>55.4 ± 25.8</td>
<td>54.6 ± 18.7</td>
<td>56.1 ± 24.8</td>
</tr>
</tbody>
</table>

Data are means ± SD. Infusion rates of ANP and CNP are expressed in µg·kg⁻¹·min⁻¹. For each period, the value is the mean of 2 (0.005, 0.01, 0.05, and recovery) or 4 (baseline) recordings or calculations. ANP and CNP had no significant effect on mean arterial pressure (MAP) (ANP: F = 0.2, NS; CNP: F = 0.3, NS), heart rate (HR) (ANP: F = 1.2, NS; CNP: F = 0.1, NS), forearm blood flow (FBF) (ANP: F = 1.6, NS; CNP: F = 0.7, NS), or forearm vascular resistance (FVR) (ANP: F = 1.1, NS; CNP: F = 0.6, NS).
plasma ANP concentration, markedly increased diuresis and natriuresis and additionally increased GFR. RPF remained unchanged and filtration fraction increased in response to 0.05 µg·kg$^{-1}$·min$^{-1}$ ANP. Infusion of CNP similar caused increase in filtration fraction due to a slight, nonsignificant increase in GFR. However, the natriuretic response to CNP was only one-half as large as that to ANP at a similar infusion rate and was not associated with any change in diuresis. These results are consistent with previous studies showing weaker renal effects of CNP compared with ANP. In laboratory animals, a weak renal effect (8) or an antinatriuretic effect of CNP has been found, depending on the experimental conditions, the species, and the effect of CNP on hemodynamics (9, 27). In normal humans given CNP at infusion rates similar to those used in our study, Hunt et al. (16) failed to detect any effect of CNP on diuresis, natriuresis, or urinary cGMP. Because blood pressure remained unchanged in this study, alterations in systemic hemodynamics could not explain the lack of renal action of the peptide (16). In another study, Igaki et al. (17) observed that the natriuretic response to ∼1 µg/kg CNP given by bolus injection in normal humans was less marked than that induced by similar doses of ANP. Taken in concert, these results suggest that CNP has a weaker natriuretic effect than ANP when administered intravenously in humans and that its natriuretic action occurs without important changes in diuresis. Consistent with this suggestion, urinary cGMP excretion increased to a greater extent in response to ANP than to CNP in our study. Infusion of ANP caused marked rises in both plasma cGMP concentration and nephrogenous cGMP, whereas CNP infusion did not increase plasma cGMP concentration and only produced a slight elevation in nephrogenous cGMP. Because CNP and ANP preferentially bind to ANPR-B and ANPR-A, respectively, this result may be interpreted as a predominance of ANPR-A over ANPR-B in the kidney. Support for this hypothesis can be found in a study in rats showing that binding to ANPR-B was not detectable in the rat kidney and that smaller amounts of cGMP were produced by isolated glomeruli in response to CNP than to ANP (5). However, the expression of ANPR-B has been demonstrated in the human kidney (6), and several studies have recently provided evidence for a

---

Table 3. Effects of ANP and CNP infusions on PRA and plasma aldosterone

<table>
<thead>
<tr>
<th></th>
<th>Baseline 1</th>
<th>Baseline 2</th>
<th>30 min 0.005</th>
<th>60 min 0.005</th>
<th>0.01</th>
<th>0.05</th>
<th>Recovery</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PRA, ng·ml$^{-1}$·h$^{-1}$</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>15 ± 0.6</td>
<td>13 ± 0.5</td>
<td>13 ± 0.4</td>
<td>14 ± 0.4</td>
<td>15 ± 0.6</td>
<td>14 ± 0.7</td>
<td>14 ± 0.7</td>
</tr>
<tr>
<td>ANP</td>
<td>11 ± 0.3</td>
<td>13 ± 0.5</td>
<td>1 ± 0.4</td>
<td>1 ± 0.4</td>
<td>11 ± 0.5</td>
<td>11 ± 0.5</td>
<td>12 ± 0.5</td>
</tr>
<tr>
<td>CNP</td>
<td>11 ± 0.5</td>
<td>14 ± 0.8</td>
<td>13 ± 0.5</td>
<td>12 ± 0.4</td>
<td>12 ± 0.4</td>
<td>12 ± 0.3</td>
<td>12 ± 0.5</td>
</tr>
<tr>
<td><strong>Aldosterone, pg/ml</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>27.1 ± 20.7</td>
<td>28.8 ± 24.7</td>
<td>24.0 ± 20.9</td>
<td>22.8 ± 20</td>
<td>23.8 ± 26.7</td>
<td>40.1 ± 26.3</td>
<td>40.1 ± 26.3</td>
</tr>
<tr>
<td>ANP</td>
<td>30.4 ± 10.1</td>
<td>58.1 ± 72.3</td>
<td>44 ± 54.4</td>
<td>30.2 ± 16.2</td>
<td>52.3 ± 59.8</td>
<td>47.3 ± 59.6</td>
<td>35.2 ± 38.7</td>
</tr>
<tr>
<td>CNP</td>
<td>43.9 ± 31.2</td>
<td>41.4 ± 21.7</td>
<td>29.4 ± 22.4</td>
<td>47.1 ± 52.2</td>
<td>51.9 ± 71.9</td>
<td>32.7 ± 36.3</td>
<td>62.7 ± 48.6</td>
</tr>
</tbody>
</table>

Values are means ± SD. Infusion rates ANP and CNP are expressed in µg·kg$^{-1}$·min$^{-1}$. Effects of ANP and CNP were not significant on plasma renin activity (PRA) (ANP: F = 1, NS; CNP: F = 0.7, NS) and plasma aldosterone (ANP: F = 0.4, NS; CNP: F = 1.2, NS).
local production of CNP in the proximal tubule either in rat or human kidney (12, 22, 24, 32). These results open up the possibility that CNP may preferentially act as a paracrine factor. If this is indeed the case, the weak renal response to exogenous CNP infusion in humans may not reflect the physiological importance of the peptide. The fact that CNP was not detectable in the plasma during basal conditions is consistent with this hypothesis. An alternative hypothesis is that the changes in renal parameters measured during infusion of CNP reflected activation of ANPR-A rather than ANPR-B by CNP and that weaker affinity of CNP compared with ANP for ANPR-A explained the weak renal response to CNP. Such an hypothesis is unlikely, because in vitro potency of CNP for cGMP production by ANPR-A is 300- to 700-fold lower than that of ANP and because the increase in nephrogenous cGMP in the present study was only 10-fold lower with CNP than with ANP. Another possibility is that CNP infusion, which caused a slight increase in plasma ANP concentration (probably due to CNP displacing ANP from clearance receptors), may have induced subsequent ANP-mediated activation of ANPR-A. Several investigators have also reported a slight increase in plasma ANP during exogenous CNP infusion (8, 9, 16). However, the plasma ANP peak during CNP infusion in our study remained lower than that obtained with the lowest ANP infusion rate, which had no natriuretic effect (43 vs. 65 pg/ml) in the same subjects. Therefore, it is unlikely that this mechanism contributed to the renal effects of CNP infusion in our normal subjects.

In our study, neither ANP nor CNP produced any changes in arterial pressure, heart rate, and FBF. There have been many reports that ANP induced only small changes on blood pressure when administered in low doses in laboratory animals (2, 15, 25) and normal humans (3, 14, 26). In contrast, studies in dogs have found that CNP induced a marked decrease in blood pressure due to decreases in venous return and cardiac output (9, 27). Systemic hypotension was more marked in response to infusion of CNP than to infusion of ANP (9). This hypotensive action of CNP is consistent with the potent venodilator effect of CNP in vitro (33). In contrast, studies performed in humans using either

![Fig. 6. Changes in plasma cGMP concentrations (A), urinary cGMP excretion (U_{cGMP}; B), and renal cGMP production (nephrogenous cGMP; C) in response to saline (control) and to incremental infusion rates of ANP or CNP. Two-way ANOVA for repeated measurements showed significant increases in plasma (F = 4.8; P < 0.01), urinary (F = 17.3; P < 0.001), and nephrogenous cGMP (F = 11; P < 0.001) in response to ANP. Infusion of CNP increased only urinary (F = 4.1; P < 0.001) and nephrogenous (F = 6; P < 0.05) cGMP. *P < 0.05, **P < 0.01, ***P < 0.001 vs. saline infusion (control).](http://ajpregu.physiology.org/)

![Fig. 7. Correlation between changes in peptides plasma levels in response to the infusions according to the rate of infusion. ANP: open squares and dashed line, CNP: filled circles and solid line.](http://ajpregu.physiology.org/)
CNP infusion rates similar to ours or injection of a 1 µg/kg bolus failed to demonstrate any effect of CNP on blood pressure (7, 16, 17). In our study, it is unlikely that CNP infusion caused a decrease in venous return, because blood pressure, FBF, and vascular resistance remained unchanged. Thus our results do not support an important role for circulating CNP in the modulation of vascular tone in normal men. However, a high level of ANPR-B expression has been demonstrated for smooth muscle cells in culture (30), and CNP has been shown to relax isolated vascular preparations (33). It is therefore possible that CNP produced by endothelial cells also acts preferentially as a paracrine factor in arteries or veins.

Rapid degradation of CNP by clearance receptors or neutral endopeptidase may explain the modest vascular actions of CNP and its weaker renal effects compared with ANP (19, 21). ANP and CNP share the same pathways of degradation by neutral endopeptidase and clearance receptors. In vitro, evidence has been reported that CNP may be a better substrate than ANP or BNP for neutral endopeptidase with a faster rate of hydrolysis and a lower $K_m$ (18). In contrast, the affinity of CNP for the clearance receptor is three- to fivefold lower than that of ANP (30). In vivo, the half-life of CNP was slightly lower than that of ANP, consistent with faster degradation (16). Brandt et al. (4) recently reported that catabolism of CNP via the clearance receptor was predominant in the lungs, whereas degradation via neutral endopeptidase was the main pathway in the kidney and the peripheral vasculature. In our study, it is difficult to compare the degradation of ANP and CNP on the basis of plasma concentrations and infusion rates. When expressed in molar concentrations, the infusion-induced changes in ANP and CNP concentrations were similar in magnitude, suggesting that under our experimental conditions the two peptides were degraded at similar rates. Further experiments with a neutral endopeptidase inhibitor would be required to assess the exact role of the enzymatic pathway in CNP degradation.

ANP has been shown to decrease PRA and plasma aldosterone in normal humans and in heart failure patients (10). CNP is also a potent inhibitor of aldosterone production by adrenal gland in vitro (11). However, the in vivo effects of CNP on the renin-angiotensin system remain controversial. In one study, CNP had no effect on PRA but increased plasma aldosterone in awake dogs (Am. J. Physiol. 254 (Regulatory Integrative Comp. Physiol, 23): R161–R169, 1988). Biellier et al. (1, 17, 19) have shown that CNP has a strong diuretic effect, with increases in fractional excretion of sodium, urinary cGMP, and nephrogenous cGMP in normal men. However, these effects were only two- to threefold lower than those produced by equivalent doses of ANP. Because circulating CNP levels are low in normal humans, these results suggest that CNP may differ from ANP in that it may act as a paracrine factor rather than as an endocrine factor. Inhibition of the peptide degradation by neutral endopeptidase blockade might potentiate both the endocrine and the paracrine effects of the peptide. Future studies using neutral endopeptidase inhibitors may provide additional information on the specific vascular and renal effects of CNP.

We thank Lilianne Forest, Monique Deriot, Frédéric Thieffry, Annie Duperat, and Robert Herregault for technical assistance. Address for reprint requests: I. Pham, Service de Physiologie et d’Explorations Fonctionnelles, Hôpital Henri Mondor, 51 Av du Maréchal de Lattre de Tassigny, 94000 Créteil, France. Received 24 September 1996; accepted in final form 7 July 1997.

REFERENCES


12. Dean, A. D., M. Vehaskari, and J. E. Greenwald. Synthesis and localization of C-type natriuretic peptide mammalian kid-
R1464 C-TYPE AND ATRIAL NATRIURETIC PEPTIDES IN HUMANS


